On the 30th, Access Bio announced that it has invested 5 billion won in Wellysis, a wearable ECG (electrocardiogram) specialist. The investment was made through the acquisition of convertible preferred shares issued by Wellysis through the Mason Healthcare New Technology Investment Fund No. 2.

Wellisys, spun off from Samsung SDS's digital healthcare business unit in 2019, successfully launched the 'S-Patch' series, a cardiac measurement device that accurately and rapidly diagnoses cardiovascular diseases. Currently, it provides commercial services in 14 countries, including the UK, Italy, Australia, and Singapore, and is rapidly growing.

With this investment, Access Bio plans to strengthen its digital healthcare business by securing the US rights to Wellysis products and collaborating on business and technology.

CEO Choi Young-ho stated, "Many healthcare companies in Korea, known for their excellent technology, aim to enter the largest medical market in the world, the US. However, realistically, the entry barriers are high and it is not easy." He added, "Access Bio, founded in the US in 2002, has expertise in obtaining US FDA approval for diagnostic kits. Therefore, we can provide a solid foundation for Wellysis's entry into the US market."

AccessBio plans to grow by combining Wellysis's platform technology with its own diagnostic products, enabling real-time monitoring, analysis, tracking, and remote patient management.

CEO Choi Young-ho explained, "Since its establishment, our company has focused on 'clinic-centered treatment.' Through cooperation with Wellysis, we will maximize the synergy of IT convergence in our specialty field of diagnostics and leap forward as a digital healthcare specialist."

Wellysis's S-Patch consists of wearable ECG monitoring devices and a cloud-based ECG artificial intelligence analysis system. When attached to the chest, the Samsung bio-processor, a semiconductor chip specialized in collecting bio-signals, collects ECG data from the patient's daily life. The collected ECG data is then analyzed by AI-based software and provided to medical professionals.

Wellysis released the 2nd-generation product of S-Patch, S-Patch Ex, last year and is conducting clinical trials at institutions such as Stanford Medical School in the US, the UK National Health Service, and Severance Hospital.